Zobrazeno 1 - 10
of 7 915
pro vyhledávání: ''
Autor:
Daniela Bohr, K. Manger, Bernhard Manger, Georg Schett, Verena Schoenau, Thomas Harrer, Gerhard Krönke, Arnd Kleyer, David Simon, Koray Tascilar, Filippo Fagni, Johannes Knitza, Katja Schmidt, Andreas Ramming
Publikováno v:
Annal of the Rheumatic Diseases
ObjectivesTotestwhether patients with immune-mediated inflammatory disease (IMIDs), who did not respond to two doses of the SARS-CoV-2 vaccine, develop protective immunity, if a third vaccine dose is administered.MethodsPatients with IMID who failed
Autor:
Vivian E, Saper, Michael J, Ombrello, Adriana H, Tremoulet, Gonzalo, Montero-Martin, Sampath, Prahalad, Scott, Canna, Chisato, Shimizu, Gail, Deutsch, Serena Y, Tan, Elaine F, Remmers, Dimitri, Monos, Timothy, Hahn, Omkar K, Phadke, Elaine, Cassidy, Ian, Ferguson, Vamsee, Mallajosyula, Jianpeng, Xu, Jaime S, Rosa Duque, Gilbert T, Chua, Debopam, Ghosh, Ann Marie, Szymanski, Danielle, Rubin, Jane C, Burns, Lu, Tian, Marcelo A, Fernandez-Vina, Elizabeth D, Mellins, Jill A, Hollenbach, Claudio, Len
Publikováno v:
Annals of the Rheumatic Diseases. 81:406-415
ObjectivesDrug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, delayed hypersensitivity reaction (DHR). We observed DRESS to inhibitors of interleukin 1 (IL-1) or IL-6 in a small group of patients with Still’s disease with aty
Publikováno v:
Annals of the Rheumatic Diseases. 81:11-14
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that manifests primarily in the axial skeleton, initially mostly in the sacroiliac joints (SIJ), usually later spreading to the spine. The disease is characterised by inflamm
Autor:
J Garg, Analia Alvarez, Elizabeth Zuta-Santillan, Paul Brunetta, Ana Malvar, Cary M. Looney, Brad H. Rovin, Thomas Schindler, Richard Furie, Matthew D Cascino, Imran Hassan, Gustavo Aroca, Hilda Fragoso-Loyo
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveRandomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell d
Autor:
Gertjan Wolbink, Radboud J E M Dolhain, Hieronymus T W Smeele, Erik Kemper, Theo Rispens, Ineke Hubertina Crijns, Nafise Ghalandari
Publikováno v:
Annals of the Rheumatic Diseases, 81(3), 402-405. BMJ Publishing Group
Annals of the rheumatic diseases, 81(3), 402-405. BMJ Publishing Group
Ghalandari, N, Kemper, E, Crijns, I H, Wolbink, G, Rispens, T, Smeele, H T & Dolhain, R J 2022, ' Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy ', Annals of the Rheumatic Diseases, vol. 81, no. 3, pp. 402-405 . https://doi.org/10.1136/annrheumdis-2021-221036
Annals of the rheumatic diseases, 81(3), 402-405. BMJ Publishing Group
Ghalandari, N, Kemper, E, Crijns, I H, Wolbink, G, Rispens, T, Smeele, H T & Dolhain, R J 2022, ' Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy ', Annals of the Rheumatic Diseases, vol. 81, no. 3, pp. 402-405 . https://doi.org/10.1136/annrheumdis-2021-221036
Background: Increasing evidence suggests that TNF inhibitors (TNFi) are safe to use during pregnancy1. A drawback of TNFi use during pregnancy is active transport across the placenta, which is affected by the structure of the TNFi1. The European Leag
Autor:
Anja Strangfeld, Ana M. Rodrigues, Loreto Carmona, Ludovic Trefond, Charalampos Papagoras, Laure Gossec, N Roux, Kimme L. Hyrich, Saskia Lawson-Tovey, Bernd Raffeiner, Elsa F Mateus, Gözde Kübra Yardımcı, Pedro Machado, Xavier Mariette
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Lawson-Tovey, S, Hyrich, K L, Gossec, L, Strangfeld, A, Carmona, L, Raffeiner, B, Yardımcı, G K, Trefond, L, Roux, N, Rodrigues, A, Papagoras, C, Mateus, E F, Mariette, X & Machado, P M 2021, ' SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2021-221217
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Annals of the Rheumatic Diseases, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Lawson-Tovey, S, Hyrich, K L, Gossec, L, Strangfeld, A, Carmona, L, Raffeiner, B, Yardımcı, G K, Trefond, L, Roux, N, Rodrigues, A, Papagoras, C, Mateus, E F, Mariette, X & Machado, P M 2021, ' SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2021-221217
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are often treated with immunomodulatory or immunosuppressive medications; consequently, they have been excluded alongside other immunocompromised patients from late stages of S
Autor:
Michael Bonelli, Stephan Blüml, Philipp Hofer, Leonhard X. Heinz, Stefan Winkler, Daniela Sieghart, Josef S Smolen, Marianne Graninger, Daniel Aletaha, Karin Stiasny, Helmuth Haslacher, Helga Radner, Selma Tobudic, Maximilian Koblischke, Renate Thalhammer, Thomas Perkmann, Daniel Mrak, Judith H. Aberle
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesEvidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a humoral and T-cell-mediated immune response against SARS-C
Autor:
María Laura Acosta Felquer, Luciano LoGiudice, Enrique R. Soriano, María Laura Galimberti, Luis Daniel Mazzuoccolo, Javier Rosa
Publikováno v:
Annals of the Rheumatic Diseases. 81:74-79
ObjectivesTo compare the incidence of psoriatic arthritis (PsA) in patients with psoriasis (PsO) according to different treatments for their skin: topics/no treatment, conventional disease-modifying antirheumatic drugs (DMARDs) (cDMARDs) or biologica
Publikováno v:
Annals of the Rheumatic Diseases. 80:1393-1399
BackgroundHepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence a
Autor:
Antonio Manzo, Silvia Balduzzi, Eleonora Mauric, Laura Bogliolo, Fausto Baldanti, Terenzj Luvaro, Bernardo D’onofrio, Daniele Lilleri, Serena Bugatti, Maria Immacolata Greco, Ludovico De Stefano, Michele di Lernia, Irene Cassaniti, Iolanda Mazzucchelli, Carlomaurizio Montecucco
Publikováno v:
Annals of the Rheumatic Diseases. 80:1635-1638
Strategies aimed at expediting immunisation campaigns against COVID-19 include providing single vaccine doses to individuals with previous exposure to SARS-CoV-2 and delaying second doses. While such approaches are effective at the population level,